stockportfolio.pro
Amgen Inc. (AMGN)
Healthcare · Drug Manufacturers - General · NasdaqGS
Amgen Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.99B | $22.85B | $23.75B | $23.36B | $25.42B | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
| Gross profit | $18.83B | $18.78B | $19.65B | $19.01B | $19.27B | $19.52B | $19.92B | $19.74B | $20.57B | $24.71B |
| Net income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B |
| Net margin | 33.6% | 8.7% | 35.3% | 33.6% | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
Source: Amgen Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into AMGN stock?
At today's market cap of $185.96B, Amgen Inc. is priced for free-cash-flow growth of about 9.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $8.10B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -3.9%/yr over the last five fiscal years and revenue 7.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Amgen Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AMGN in your portfolio →
Amgen Inc. financial history by metric
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. — frequently asked questions
What is Amgen Inc.'s revenue?
Amgen Inc. (AMGN) reported revenue of $36.75B for fiscal year 2025, up 10.0% from the prior year, according to its SEC filings.
Is Amgen Inc. profitable?
Yes. AMGN earned net income of $7.71B in fiscal 2025, a net margin of 21.0%.
What is AMGN's P/E ratio?
Amgen Inc. trades at a price-to-earnings ratio of about 24.0 based on the latest data in our nightly-refreshed cache.
How fast is Amgen Inc. growing?
AMGN's revenue grew at roughly 7.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Amgen Inc. have?
As of fiscal year 2025, AMGN carried roughly $54.60B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Amgen Inc.'s gross margin?
AMGN's gross margin was 67.2% in fiscal 2025 — gross profit of $24.71B on revenue of $36.75B.
What is Amgen Inc.'s market cap?
Amgen Inc. (AMGN) has a market capitalization of about $185.96B, based on the latest data in our nightly-refreshed cache.
When does Amgen Inc.'s fiscal year end?
AMGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into AMGN stock?
At today's market cap of $185.96B, Amgen Inc. is priced for free-cash-flow growth of about 9.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $8.10B from the FY ending 2025-12-31). For comparison, free cash flow actually grew -3.9%/yr over the last five fiscal years and revenue 7.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Amgen Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.